NCT05323747 2025-09-16
BP-008
BioProtect
Completed
Clinical Trials
10 trialsNCT05354427 2025-09-16
CLP-10095
BioProtect
Completed
NCT04528407 2025-02-13
BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects
BlueSky Immunotherapies GmbH
Completed
NCT05775549 2024-09-20
FLAME
AstraZeneca
Completed
NCT04060290 2024-02-28
Real-world Study for the Safety of Albumin-Bound Paclitaxel in Malignant Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Completed
NCT02733601 2023-04-03
BreCaReAl
AstraZeneca
Completed
NCT04807595 2023-03-06
Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status
AstraZeneca
Completed
NCT05423431 2022-06-24
Retrospective Evaluation of a Commercially Available Hydrogel Spacer (BP-009)
BioProtect
Completed
NCT00759109 2017-04-07
Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00754000 2012-04-30
AIM
Varian, a Siemens Healthineers Company
Completed